[Inhibitory effect of AS-35. a novel antiallergic drug, on chemical mediator release from human eosinophils].
To determine whether AS-35, a new antiallergic drug, inhibits the activation of eosinophils, we examined the effect of AS-35 on the release of leukotriene C4 (LTC4) and eosinophil peroxidase (EPO) from human eosinophils. Calcium ionophore A23187 caused both LTC4 and EPO release from human eosinophils. AS-35 (1 x 10(-5) M) inhibited A23187-induced LTC4 release from the eosinophils with 56% inhibition. AS-35 (1 x 10(-6) to 1 x 10(-5) M) also inhibited A23187-induced EPO release from the eosinophils in a dose-dependent fashion with 79% inhibition at 1 x 10(-5) M. We concluded that AS-35 prevents the activation of human eosinophils to inhibit LTC4 and EPO release. These results suggest that AS-35 might be useful in controlling allergic diseases by inhibiting eosinophil activation.
Kawashima
T
T
Research Laboratories, Tokyo Tanabe Co. Ltd.
Nagaki
S
S
Iwakaji
A
A
Iwamoto
I
I
Yoshida
S
S
Tomioka
H
H
D002478:Cells, Cultured; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D017997:Leukotriene C4 / Q000378:metabolism*; D010544:Peroxidases / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology*; D011744:Pyrimidinones / Q000494:pharmacology*; D013777:Tetrazoles / Q000494:pharmacology*
D011725:Pyridines; D011744:Pyrimidinones; D013777:Tetrazoles; C073308:AS 35; D017997:Leukotriene C4; D047209:Eosinophil Peroxidase; D010544:Peroxidases